“Increasingly, we can build on the excellent results of our basic research and transfer them to the clinic. For successful translation, we need strong partners: both in the clinic, where we can rely on the National Center for Tumor Diseases (NCT) in Heidelberg and on the German Consortium for Translational Cancer Research, and in industry. The strategic alliance with Bayer HealthCare over the past five years has been extremely successful. Together we are able to advance promising projects with the prospect of reaching the clinic and hopefully the patients. We are pleased to continue this alliance for another five years," explained Prof. Dr. Dr. h.c. Wiestler, CEO of the German Cancer Research Center.
“We are looking forward to another five years of fruitful collaboration with the DKFZ. Together we have already initiated twenty-eight projects and twelve projects have reached important milestones," said Prof. Dr. Andreas Busch, Member of the Bayer HealthCare Executive Committee and Head of Global Drug Discovery. “The DKFZ’s scientific excellence as Germany’s largest biomedical research institute perfectly matches with Bayer’s proven drug discovery and development expertise. There is still a huge medical need in the treatment of a number of tumor types and cancer in general. This alliance demonstrates Bayer’s ongoing commitment to develop innovative therapies that can help patients suffering from cancer."